Business
Proteome Sciences form allian
Proteome Sciences form allian.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n RNS Number : 1377W Proteome Sciences PLC 15 November 2010 \n \n\n\n\n\n\nDate:\n\n\n15 November 2010\n\n\n\n\nOn behalf of:\n\n\nProteome Sciences plc\n\n\n\n\nEmbargoed for release at:\n\n\n0700 hrs\n\n\n\n\n \nProteome Sciences and ICON Partner for the Delivery of Comprehensive Biomarker Solutions \n \nLondon, 15 November, 2010: Proteome Sciences plc (AIM:PRM) a leading provider of protein biomarker discovery, validation, and assay development services, and, ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announce the formation of a strategic alliance to provide pharmaceutical companies with an expanded biomarker solution to allow earlier assessments in the development of new medicines. \n \nThrough the alliance with Proteome's PS Biomarker Services™, ICON is able to provide a strengthened biomarker solution to include Proteome Sciences' unique integrated suite of labeling, separation and mass spectrometry technologies for protein and peptide profiling in complex biological materials.\n \nProteome Sciences and ICON are already engaged in their first joint project which is the development of a mass spectrometry assay for a key biomarker for an international pharmaceutical development company.\n \nCommenting on the initiation of this project, John Allinson, VP Biomarker Lab Services, ICON Development Solutions stated: \"We are extremely pleased to be entering this long-term partnership with Proteome Sciences which allows us to offer our clients access to state of the art protein and peptide profiling and rapid development of mass spectrometry assays through PS Biomarker Services™. This complements ICON's extensive portfolio of biomarker development and analysis services to help sponsors identify, implement and interpret the right biomarkers to inform their pre-clinical and clinical drug development.\" \n \nDr. Ian Pike, Proteome Sciences' Chief Operating Officer added: \"We are delighted to be partnering with the team at ICON Development Solutions to provide their clients with a complete biomarker solution, including PS Biomarker Discovery Services™ as part of wider clinical development programs. The unique power of our proprietary technology p...